8-K: PDS Biotech Prioritizes Triple Combination Therapy for Head and Neck Cancer Following Promising Trial Results

PDS Biotechnology is shifting its clinical focus to a triple combination therapy for advanced head and neck cancer after observing strong survival and response rates in a Phase 2 trial.

Summary

• PDS Biotechnology has announced a strategic update to its clinical development plan, prioritizing a triple combination therapy of PDS01ADC, Versamune HPV, and KEYTRUDA for advanced head and neck cancer.
• This decision follows compelling Phase 2 trial data showing a 75% three-year survival rate and a 75% overall response rate in patients with advanced head and neck cancer using the triple combination.
• The company is focusing on recurrent metastatic HPV-positive head and neck squamous cell cancer (HNSCC), where there is a significant unmet medical need.
• PDS Biotech has had discussions with the FDA regarding the design of a pivotal clinical trial for this triple combination, with the trial expected to begin in 2024.
• The company reported a net loss of $42.9 million for the year ended December 31, 2023, compared to a net loss of $40.9 million in 2022.
• Research and development expenses decreased to $27.8 million in 2023 from $29.4 million in 2022, while general and administrative expenses increased to $15.3 million from $12.2 million.
• The company's cash balance as of December 31, 2023, was $56.6 million.
• PDS Biotech raised approximately $10.5 million in net proceeds from its at-the-market sales agreement during the fourth quarter of 2023.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a clear strategic direction, which is encouraging for investors. However, the company's financial losses and need for additional funding temper the overall sentiment slightly.

Positives

• The triple combination therapy shows significant promise with a 75% three-year survival rate in advanced head and neck cancer patients.
• The company has received clear guidance from the FDA on the trial design and regulatory pathway for the pivotal trial.
• The safety profile of PDS01ADC has been demonstrated in over 300 cancer patients.
• The company has a strong cash balance of $56.6 million.
• The company has appointed experienced leaders to key positions.

Negatives

• The company reported a net loss of $42.9 million for the year ended December 31, 2023, which is higher than the $40.9 million loss in 2022.
• The company's cash balance decreased from $73.8 million at the end of 2022 to $56.6 million at the end of 2023.
• The company has an accumulated deficit of $144.5 million.
• The company's 10-K for the year ended 12/31/2023 includes a going concern opinion.

Risks

• The company's ability to protect its intellectual property rights is a risk.
• The company is dependent on additional financing to fund its operations and complete the development and commercialization of its product candidates.
• The company has a limited operating history in its current line of business, making it difficult to evaluate its prospects.
• The success of the planned clinical trials for PDS01ADC, PDS0101, and other product candidates is not guaranteed.
• The company's ability to continue as a going concern is a risk.

Future Outlook

The company plans to initiate a pivotal clinical trial in 2024 for its triple combination therapy in advanced head and neck cancer and expects to provide an update on regulatory confirmation of the study in Q2/Q3 2024.

Management Comments

• We have obtained compelling data from several Phase 2 trials in the fourth quarter of 2023, including long-term survival data from the National Cancer Institute (NCI)-led triple combination trial of PDS01ADC in combination with Versamune HPV (PDS0101) and an investigational immune checkpoint inhibitor (ICI), as well as our VERSATILE-002 study, said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech.
• We now have a better understanding of how our drug platform technology works in advanced cancer, and we have therefore made the strategic, data-driven decision to add our novel, investigational IL-12 fused antibody drug conjugate, PDS01ADC, to the promising combination of Versamune HPV and KEYTRUDA to advance the triple combination as our top clinical development priority, said Dr. Bedu-Addo.
• The data suggest that the triple combination may result in a significant improvement in overall survival rates for patients who currently lack an effective treatment option, said Dr. Bedu-Addo.
• A clear unmet need is seen in HPV+ HNSCC with few agents being studied in this population due to the difficulty in treating advanced HNSCC, said Kirk V. Shepard, M.D., Chief Medical Officer of PDS Biotech.
• A controlled randomized clinical trial that builds upon the current data is warranted, and I am intrigued by the potential of this unique combination to treat HNSCC, said Katharine A. Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center and Principal Investigator of PDS Biotechs upcoming triple combination trial.

Industry Context

The focus on a triple combination therapy addresses the challenges of treating advanced head and neck cancer, where current immunotherapies often face limitations due to the tumor microenvironment. The company's approach of combining an antibody drug conjugate, a T-cell activator, and an immune checkpoint inhibitor is aligned with the industry's trend of exploring combination therapies to improve patient outcomes.

Comparison to Industry Standards

• The reported 75% three-year survival rate in the NCI-led triple combination trial is significantly higher than the approximately 20% three-year survival rate seen with immune checkpoint inhibitors alone in similar patient populations, as published in medical literature.
• The overall response rate of 75% with the triple combination is also notably higher than the <40% overall response rate typically seen with immunotherapeutic agents in this setting.
• In ICI-resistant patients, the 12-month overall survival rate of 72% with the triple combination is substantially better than the published 12-month OS rate of ~30% and median OS of 3.4 months in HPV-positive ICI-resistant cancer.
• These results suggest that PDS Biotech's triple combination therapy may offer a significant improvement over existing treatment options for advanced head and neck cancer, potentially positioning it as a leader in this space.

Management Changes

Stakeholder Impact

• Shareholders may benefit from the company's focus on a promising therapy and potential for increased value.
• Patients with advanced head and neck cancer may benefit from a new treatment option with improved survival rates.
• Employees may be impacted by the company's strategic shift and focus on the triple combination therapy.
• Creditors may be impacted by the company's financial performance and need for additional funding.

Next Steps

• The company plans to initiate a pivotal clinical trial for the triple combination therapy in 2024.
• The company expects to provide an update on regulatory confirmation of the potentially registrational study in Q2/Q3 2024.
• The company expects a readout of the VERSATILE-002 Phase 2 trial in April 2024.
• The company will confirm the path to a triple combination Phase 1/2 study in r/m colorectal cancer in Q4 2024.

Key Dates

Keywords

PDS01ADC, Versamune HPV, KEYTRUDA, head and neck cancer, HNSCC, immunotherapy, clinical trial, FDA, oncology, cancer treatment